Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
Source: View publication →
The ACHIEVE-4 trial demonstrated that the novel oral non-peptide GLP-1 receptor agonist orforglipron is non-inferior to insulin glargine regarding major adverse cardiovascular events in adults with type 2 diabetes and high cardiovascular risk.
Key Findings
Study Design
Study Limitations
Clinical Significance
ACHIEVE-4 confirms the cardiovascular safety of orforglipron, marking a significant milestone for non-peptide oral GLP-1 receptor agonists. Because orforglipron circumvents the strict fasting and water administration restrictions associated with existing oral peptide formulations (like oral semaglutide), it represents a highly convenient therapeutic option for patients with type 2 diabetes. Furthermore, compared to basal insulin, it provides effective glycemic management with a substantially lower risk of clinically significant hypoglycemia.
Historical Context
While injectable peptide-based GLP-1 receptor agonists (such as liraglutide, dulaglutide, and semaglutide) have well-established cardiovascular benefits, their injectable nature poses a barrier to some patients. Oral semaglutide exists but requires strict administration conditions. Orforglipron is an oral, non-peptide GLP-1 receptor agonist designed to offer easier administration. Establishing its cardiovascular safety profile in high-risk patients with type 2 diabetes was a necessary regulatory and clinical hurdle before it could be broadly adopted as a front-line metabolic therapy.
Guided Discussion
High-yield insights from every perspective
How does the biochemical structure of orforglipron differ from other oral GLP-1 receptor agonists like oral semaglutide, and why is this clinically significant for medication administration?
Key Response
Orforglipron is a non-peptide small molecule, unlike peptide-based GLP-1 RAs. This structure protects it from degradation by gastric enzymes in the stomach, allowing oral administration without the strict fasting and water absorption requirements of oral semaglutide (which requires a SNAC absorption enhancer), thereby significantly reducing barriers to patient adherence.
When initiating a patient on orforglipron instead of insulin glargine for advanced type 2 diabetes with high cardiovascular risk, how does the expected side effect profile differ, and what anticipatory counseling is essential?
Key Response
Orforglipron primarily causes gastrointestinal side effects such as nausea, vomiting, and delayed gastric emptying, but carries a much lower risk of hypoglycemia compared to insulin glargine. Counseling should focus on slow dose titration, eating smaller meals, and dietary modifications to mitigate GI distress, whereas glargine requires extensive counseling on hypoglycemia management and injection technique.
ACHIEVE-4 demonstrated non-inferiority for MACE. Given that several injectable GLP-1 RAs have demonstrated MACE superiority in trials like SUSTAIN-6 and LEADER, how should we interpret the lack of superiority of this novel agent compared to an active comparator?
Key Response
The use of an active comparator (insulin glargine) rather than a placebo significantly complicates superiority assessments, as intensive glycemic control with glargine itself may confer certain vascular benefits over time. Assessing whether the lack of superiority is due to the non-peptide structure, differing GLP-1 receptor binding kinetics, or simply the statistical realities of an event-driven active-comparator design is crucial for positioning orforglipron in the treatment algorithm.
How does the availability of a highly effective, easily administered oral non-peptide GLP-1 RA shift our paradigm for early aggressive risk factor modification in the primary care setting versus specialized endocrinology clinics?
Key Response
An oral GLP-1 RA that bypasses complex fasting requirements removes major adherence barriers associated with both injections and previous oral peptides. This empowers primary care clinicians to initiate incretin therapy much earlier in the disease course, potentially deferring insulin therapy entirely and shifting the clinical focus strictly toward cardiometabolic risk reduction and weight management.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ACHIEVE-4 trial utilizes an active comparator (insulin glargine) in an event-driven non-inferiority design. What are the specific statistical and methodological challenges of establishing a valid non-inferiority margin without a placebo arm in cardiovascular outcome trials?
Key Response
Using an active comparator increases the difficulty of establishing a non-inferiority margin because the comparator may possess a non-zero effect on the outcome. The preservation of effect (PoE) must be calculated based on historical placebo-controlled trials of insulin glargine, which introduces cross-study heterogeneity and makes the determination of the strict upper bound of the 95 percent confidence interval for the hazard ratio highly complex.
As a peer reviewer evaluating the open-label design of the ACHIEVE-4 trial, how might the lack of blinding introduce detection and performance bias regarding cardiovascular endpoints, and what specific data should be requested to ensure this was mitigated?
Key Response
An open-label design can lead to differential use of cardioprotective concomitant medications (such as statins or SGLT2 inhibitors) if investigators subconsciously believe one arm is more beneficial or harmful. While a robust central, blinded clinical event adjudication committee (CEC) mitigates detection bias for the primary endpoint, reviewers must heavily scrutinize the baseline and longitudinal follow-up data to ensure concomitant medication initiation was balanced between arms.
Current ADA and EASD guidelines strongly recommend GLP-1 RAs with 'proven cardiovascular benefit' for patients with T2D and high ASCVD risk. Based on ACHIEVE-4 demonstrating non-inferiority rather than superiority to glargine, should orforglipron receive the same Level A recommendation for CV risk reduction as agents like dulaglutide or subcutaneous semaglutide?
Key Response
Guidelines explicitly distinguish between agents with proven CV benefit (superiority) versus neutral CV safety (non-inferiority). Because orforglipron achieved non-inferiority, it meets FDA mandates for cardiovascular safety but does not qualify for the specific compelling indication of independent MACE reduction. Guidelines would likely recommend it as a highly effective glucose-lowering agent with confirmed safety, but prioritize proven superior agents for strict secondary cardiovascular prevention.
Clinical Landscape
Noteworthy Related Trials
ORIGIN Trial
Tested
Insulin glargine
Population
Patients with CV risk factors and early T2DM or prediabetes
Comparator
Standard care
Endpoint
3-point MACE
LEADER Trial
Tested
Liraglutide 1.8 mg daily
Population
T2DM patients with high CV risk
Comparator
Placebo
Endpoint
3-point MACE
PIONEER 6 Trial
Tested
Oral semaglutide 14 mg daily
Population
T2DM patients with high CV risk
Comparator
Placebo
Endpoint
3-point MACE
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis